Correction: *Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial*

Emery P, Horton S, Dumitru RB, *et al*. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. *Ann Rheum Dis* 2020;79:464–71.

Abstract: results section, line 6 should read as "PD was fully suppressed by week 48 in 74-87%…" as opposed to currently stated "PD was fully suppressed by week 48 in over 90%…"

Results and 'Imaging outcomes', para 2:

a. line 3: This should read "Over 60% in each arm…" as opposed to "Over 50% in each arm…"
b. line 4–5 should read, "….by week 12 to 24%–37% in each arm, further reduced to 13%–26% by week 48…" as opposed to "….by week 12% to 15% in each arm, maintained by week 48…"

Discussion, para 4, line two should read "…US PD suppressed in both arms to 13%–26%…" as opposed to "…US PD suppressed in both arms to <13%…"

Table 1 (baseline characteristics) and table 4 (Total grey scale and Power Doppler ultrasound scores) have been updated with the correct values.

Table 1 Baseline demographics and disease profile for the entire group, ETN+MTX and MTX-TT

Variable	All	ETN+MTX	MTX-TT
Demographics			
Age, years Mean (SD)	50.0 (12.8)	49.6 (12.5)	50.3 (13.2)
Female % (n/N)	71% (85)	65% (39)	77% (46)
RA presenting history, % (n/N) (unless otherwise stated)			
Symptom duration, weeks, median (Q1, Q3)	20.3 (13.1, 30.8)	19.2 (12.5, 28.1)	20.8 (15.9, 31.9)
Previous IM steroid	1% (1/120)	0% (0/60)	2% (1/60)
Previous IA steroid	0% (0/120)	0% (0/60)	0% (0/60)
Concomitant oral steroid	3% (3/120)	0% (0/60)	5% (3/60)
Concomitant NSAID	88% (105/120)	92% (55/60)	83% (50/60)
RA disease phenotype, % (n/N)			
RF positive	73% (87/120)	70% (42/60)	75% (45/60)
ACPA positive	84% (101/120)	82% (49/60)	87% (52/60)
ANA positive	15% (18/120)	18% (11/60)	12% (7/60)
RA disease activity components, Median (Q1, Q3) (unless otherwise stated)			
TJC28	11.0 (7.0, 17.0)	11.5 (6.0, 20.0)	10.0 (7.0, 16.0)
SJC28	5.0 (2.0, 9.0)	5.0 (3.0, 10.5)	5.0 (2.0, 9.0)
ESR, mm/hr	31.5 (18.5, 51.0)	30.5 (17.0, 51.5)	32.5 (20.5, 51.0)
CRP, mg/L	8.8 (2.3, 24.0)	10.2 (1.8, 28.0)	8.0 (2.7, 21.5)
Disease activity VAS, mm Mean (SD)	57.1 (22.3)	60.7 (21.6)	53.6 (22.6)
RA disease activity scores, Mean (SD)			
DAS28-ESR	5.7 (1.1)	5.8 (1.1)	5.6 (1.0)
DAS44-ESR	3.7 (0.8)	3.7 (0.9)	3.7 (0.7)
DAS28-CRP	5.1 (1.2)	5.2 (1.2)	4.9 (1.1)
DAS44-CRP	3.4 (0.8)	3.5 (0.9)	3.3 (0.8)
SDAI	31.6 (13.7)	34.2 (14.7)	29.0 (12.3)
CDAI	29.8 (12.7)	32.2 (13.6)	27.3 (11.2)
Patient-reported outcome measures, Mean (SD) (unless otherwise stated)			
Global pain VAS, mm	53.5 (24.5)	59.0 (23.4)	48.1 (24.6)
HAQ-DI	1.2 (0.5)	1.2 (0.5)	1.1 (0.5)
RAQoL	17.3 (7.3)	16.8 (7.4)	17.9 (7.2)
In paid work % (n/N)	73% (88/120)	82% (49/60)	65% (39/60)
EQ5D-3L index	0.5 (0.3)	0.4 (0.3)	0.5 (0.3)
RAWIS	18.2 (6.6)	19.0 (6.7)	17.3 (6.4)
Ultrasound scores Median (Q1, Q3)			
Total GS score	4.0 (2.0, 6.0)	34.0 (2.0, 7.0)	3. 5 (1.05, 6.0)
Total PD score	2.0 (0.0, 4.0)	2.0 (0.0, 4.05)	02.0 (0.0, 3.0)
Total erosion score	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)
Radiographic score Median (Q1, Q3)			
Total modified Sharp score	2.5 (0.5, 6.0)	2.0 (0.5, 5.0)	2.5 (0.5, 6.3)

Ann Rheum Dis 2021;**80**:e45. doi:10.1136/annrheumdis-2019-216539corr1